These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 251094)

  • 1. Drugs in current use: thalassaemia.
    Cromdos S
    Aust Nurses J; 1978 Sep; 8(3):30-1. PubMed ID: 251094
    [No Abstract]   [Full Text] [Related]  

  • 2. Thalassemia.
    Brown EB
    Prog Clin Biol Res; 1983; 127():33-42. PubMed ID: 6889403
    [No Abstract]   [Full Text] [Related]  

  • 3. [Current treatment of thalassemia major in children].
    Lévy G; Bost M
    Pediatrie; 1980; 35(5):451-5. PubMed ID: 7422454
    [No Abstract]   [Full Text] [Related]  

  • 4. Desferrioxamine and ascorbic acid supplement in E-B thalassaemia.
    Dutta AK; Ray R; Chandra S; Bhattacharya DK
    J Assoc Physicians India; 1988 Jul; 36(7):463-4. PubMed ID: 3204100
    [No Abstract]   [Full Text] [Related]  

  • 5. High-dose chelation therapy in thalassaemia.
    Lancet; 1984 Feb; 1(8373):373-4. PubMed ID: 6141429
    [No Abstract]   [Full Text] [Related]  

  • 6. Deferoxamine treatment during early pregnancy: absence of teratogenicity in two cases.
    Vaskaridou E; Konstantopoulos K; Kyriakou D; Loukopoulos D
    Haematologica; 1993; 78(3):183-4. PubMed ID: 8375749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maintenance treatment with desferrioxamine via subcutaneous injections in a patient with HbE thalassaemia.
    van Deursen CT; Goey SH; Fickers MM
    Neth J Med; 1988 Oct; 33(3-4):178-81. PubMed ID: 3226450
    [No Abstract]   [Full Text] [Related]  

  • 8. Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs.
    Kontoghiorghes GJ; Kolnagou A
    Haematologica; 2006 Jun; 91(6 Suppl):ELT04. PubMed ID: 16785141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of psychosocial status and disease knowledge on deferoxamine adherence among thalassaemia major adolescents.
    Al-Kloub MI; Salameh TN; Froelicher ES
    Int J Nurs Pract; 2014 Jun; 20(3):265-74. PubMed ID: 24888999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival and desferrioxamine in thalassaemia major.
    Murray JA
    Br Med J (Clin Res Ed); 1982 May; 284(6326):1401. PubMed ID: 6803993
    [No Abstract]   [Full Text] [Related]  

  • 11. [Longitudinal growth of patients with homozygote beta-thalassemia during continuous subcutaneous infusion of deferoxamine].
    Krüger N; Stubbe P; Tillmann W; Schröter W
    Dtsch Med Wochenschr; 1986 Jan; 111(5):176-81. PubMed ID: 3943469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The treatment of hemosiderosis in thalassaemia major with desferrioxamine-B.
    Kirimlidis S; Philippidis P; Drossos C; Economidis J
    Helv Paediatr Acta; 1966 Sep; 21(4):343-50. PubMed ID: 5997620
    [No Abstract]   [Full Text] [Related]  

  • 13. The effective use of oxymetholone in the therapy of thalassaemia with anaemia.
    Colebatch JH; Seshadri R
    Med J Aust; 1972 Sep; 2(13):741-2. PubMed ID: 5084972
    [No Abstract]   [Full Text] [Related]  

  • 14. The management of the improved prognosis in thalassemia major.
    Modell B
    Birth Defects Orig Artic Ser; 1982; 18(7):329-37. PubMed ID: 6819016
    [No Abstract]   [Full Text] [Related]  

  • 15. [Therapy of thalassemias].
    Bender-Götze C
    Monatsschr Kinderheilkd (1902); 1979 Dec; 127(12):714-5. PubMed ID: 514281
    [No Abstract]   [Full Text] [Related]  

  • 16. Glucose tolerance and chelation therapy in patients with thalassaemia major.
    Capra L; Atti G; De Sanctis V; Candini G
    Haematologica; 1983; 68(1):63-8. PubMed ID: 6404709
    [No Abstract]   [Full Text] [Related]  

  • 17. [Thalassemia major: chelating therapy with deferoxamine].
    Abreu de Miani MS; Sanchis de Herrlein MS; Peñalver JA
    Medicina (B Aires); 1985; 45(3):231-4. PubMed ID: 3841934
    [No Abstract]   [Full Text] [Related]  

  • 18. Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers.
    Kontoghiorghes GJ
    Hemoglobin; 2006; 30(2):329-47. PubMed ID: 16798657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical management of beta-thalassemia.
    Graziano J; Piomelli S
    Tex Rep Biol Med; 1980-1981; 40():355-64. PubMed ID: 7034276
    [No Abstract]   [Full Text] [Related]  

  • 20. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review.
    Delea TE; Edelsberg J; Sofrygin O; Thomas SK; Baladi JF; Phatak PD; Coates TD
    Transfusion; 2007 Oct; 47(10):1919-29. PubMed ID: 17880620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.